Recent Updates
Recently added Catalysts
SKYE Positive Sentiment Score: 85/100

Skye Bioscience to Participate in SXSW Session on Obesity

Monday, February 24, 2025 2 min read
Key Takeaway: Skye Bioscience, a clinical-stage biopharmaceutical company, announced that its CEO, Punit Dhillon, will participate in a panel session at the SXSW Conference. The session, titled 'Weighing in on Weight Loss Medicine,' will explore future strategies for obesity management beyond the commonly used GLP-1 drugs. Taking place on March 10, 2025, in Austin, TX, the event is part of SXSW's efforts to drive discussions on health and medtech advancements. Skye is focused on developing innovative therapies for metabolic health, including its Phase 2 clinical trial of nimacimab for obesity.

Market Sentiment Analysis

POSITIVE FACTORS

  • Skye Bioscience's involvement in SXSW showcases its commitment to obesity management innovation.
  • The panel highlights emerging trends beyond traditional GLP-1 drugs, indicating potential for new solutions.
  • Participation in a renowned conference underscores the company's thought leadership in metabolic health.

Full Press Release Details

SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, is pleased to announce the participation of Punit Dhillon, Chief Executive Officer, in a South by Southwest panel session exploring the future of obesity management beyond GLP-1 drugs.
SXSW Conference Panel Session: "Weighing in on Weight Loss Medicine"
Date: Monday, March 10, 2025
Time: 10:00 AM - 11:00 AM CT
Location: Austin, TX
SXSW is renowned for converging technology, film, music, education, and culture. Known for fostering innovation and collaboration, SXSW provides a global platform for thought leaders, industry experts, and visionaries to share insights, explore emerging trends, and drive meaningful conversations. Its dedicated tracks on health and medtech spotlight groundbreaking advancements and transformative ideas shaping the future of life sciences.
About Skye Bioscience
Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2 clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: www.skyebioscience.com. Connect with us on X and LinkedIn.
ir@skyebioscience.com
LifeSci Advisors, Mike Moyer
mmoyer@lifesciadvisors.com
LifeSci Communications, Michael Fitzhugh
mfitzhugh@lifescicomms.com

Frequently Asked Questions

What is the focus of Skye Bioscience?

Skye Bioscience is dedicated to developing new therapeutic pathways for obesity and metabolic health disorders.

When will Punit Dhillon speak at SXSW?

Punit Dhillon will participate in a panel on March 10, 2025, from 10:00 AM to 11:00 AM CT.

What is nimacimab's role in Skye's research?

Nimacimab is a negative allosteric modulating antibody being tested for obesity during a Phase 2 trial.

Where can I find more information on Skye Bioscience?

Additional information is available on Skye's website at www.skyebioscience.com.

What innovative approach does Skye employ?

Skye utilizes next-generation molecules that target G-protein coupled receptors for unique therapeutics.

Tags: SKYE Viatris Investor Conferences Healthcare Skye Bioscience obesity SXSW Punit Dhillon nimacimab
Last updated: Feb 24, 2025